Palliative Quad Shot Radiation Therapy with or without Concurrent Immune Checkpoint Inhibition for Head and Neck Cancer.
Rituraj UpadhyayEmile GogineniGlenis TocajSung J MaMarcelo R BonomiPriyanka BhatejaDavid J KonieczkowskiSujith BaligaDarrion L MitchellSachin M JhawarSimeng ZhuJohn C GreculaKhaled DibsMauricio E GamezDukagjin M BlakajPublished in: Cancers (2024)
The combination of QS with concurrent ICIs was well tolerated and significantly improved local control compared to QS alone. The median OS of 9.4 months compares favorably to historical controls for patients with HNC treated with QS. This approach represents a promising treatment option for patients with HNC unsuited for curative-intent treatment and warrants prospective evaluation.